Tuesday, April 28, 2009

Telmisartan


Telmisartan (INN) (pronounced /tɛlmɪˈsɑrtən/) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. It is marketed under the trade names Pritor or Kinzal (Bayer Schering Pharma), Micardis (Boehringer Ingelheim), Telma (Glenmark Pharma), Telday (Torrent Pharmaceuticals) and Teleact D by (Ranbaxy).
Mode of action
Telmisartan ( Teli marketed by cadila pharma) is an Angiotensin Receptor Blocker (ARB) that shows high affinity for the angiotensin II type 1 (AT1) receptors, has a long duration of action, and has the longest half-life of any ARB. [1][2]
In addition to blocking the Renin-Angiotensin System (RAS), telmisartan acts as a selective modulator of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ), a central regulator of insulin and glucose metabolism. It is believed that telmisartan’s dual mode of action may provide protective benefits against the vascular and renal damage caused by diabetes and cardiovascular disease (CVD). [2]
Telmisartan has binding affinity 3000 times with AT-2 receptor than AT-1 receptor.Telmisartan is also having maximum half life in sartans - 24 Hrs.

Indication
Telmisartan is indicated in the treatment of essential hypertension. [1]

1 comment:

  1. Thanks for sharing about medical info, which I really need to catch up.

    ReplyDelete